Kornimate/medical-research-clean huggingface dataset:
study evaluating subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with advanced illness

Conditions: Opioid-Induced Constipation

Summary: this study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. the hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects.


Eligibility criteria:
inclusion criteria: * is an adult 18 years of age or older * has a diagnosis of advanced illness (ie, a terminal illness such as incurable cancer or other end-stage disease) * has a life expectancy of at least 1 month. * is receiving opioids on a regular schedule (not just as-needed or rescue doses) for the control of pain or discomfort for at least 2 weeks before the first dose of study drug. * has constipation that is caused by opioid medications. exclusion criteria: * has a known or suspected allergy to methylnaltrexone or other similar compounds (e.g. naltrexone or naloxone). * has a known or suspected mechanical gastrointestinal obstruction. * has any potential nonopioid cause of bowel dysfunction that might be a major contributor to the constipation. * has any other clinically important abnormalities as determined by the investigator that may interfere with his or her participation in or compliance with the study. * receiving opioid antagonist or partial antagonist products.

Keywords: opioid-induced constipation
a safety and efficacy trial of aliskiren 150mg , 300 mg compared to ramipril 5mg, 10mg in the elderly

Conditions: Hypertension

Summary: evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.


Eligibility criteria:
inclusion criteria: * male or female outpatients ≥ 65 years old. * patients with essential hypertension with an mssbp ≥ 140 mmhg and \< 180 mmhg, and msdbp \< 110 mmhg at visits 2 and 3. (visit 201 was deleted by the administrative changes document.) * patients must have had a difference in mssbp of ≤ 20 mmhg between visit 3 and the visit immediately prior to visit 3. * patients who were eligible and able to participate in the study, and who consented to do so after the purpose and nature of the investigation had been explained to them (written informed consent). exclusion criteria: * history of renal artery stenosis. * known keith-wagener grade iii or iv hypertensive retinopathy. * history of hypertensive encephalopathy. * current diagnosis of heart failure (new york heart association class iii-iv). * history of transient ischemic cerebral attack or cerebrovascular accident within 6 months. * history of myocardial infarction, bypass surgery, or any percutaneous coronary intervention within 6 months. * current unstable angina pectoris. patients on a stable dose of oral or topical nitrates or beta blockers for angina were acceptable. * concurrent potentially life threatening arrhythmia or symptomatic arrhythmia. * clinically significant valvular heart disease. * concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy (e.g., flomax for bph), beta blockers for angina, or beta blockers ophthalmic preparations.

Keywords: systolic hypertension hypertension aliskiren blood pressure ramipril htn
chart review: comparing the position and tilt of dental implants versus those of natural teeth

Conditions: Dental Implant

Summary: background: when placing a dental implant, it is not always possible to place it exactly in the same position as the tooth that it replaced. that might be because of how the gums and mouth are shaped, since some bone is always lost after a tooth is extracted. researchers want to study the records of people who have had dental implants. they want to check to see how much difference there is between how the implant is positioned and how the same tooth on the other side is positioned. they also want to compare how the implant is positioned compared to the tooth it replaced, when that is possible in the dental record. study design: this study will not enroll any participants. the researchers will search the database of patient records at the study clinic to find people who have had dental implants of a single molar tooth. then they will look at them to find records that include good images that they can use to compare the implant and tooth positions. researchers will then analyze the findings and write a review article.

this is a retrospective chart review. specifically, the clinic e-chart system will be used to locate patients who received implant surgery. e-charts from january 1, 2016, to january 6, 2025, with pre- and post-implant surgery tomography (cbct) documentation will be identified and used for this study. demographic and clinical data (age, sex, systemic conditions, implant details and surgical treatment outcomes) related to these cases will be collected. radiographic measurements will include the following: * on tomography: 1. buccolingual axial inclination of natural molars and implants. 2. mesiodistal axial inclination of natural molars and implants. 3. presence/absence of fenestration and/or dehiscence around implants 4. proximity to mandibular canal and/or foramen mentale * on panoramic radiograph: mesiodistal axial inclination of natural molars and implants.

Eligibility criteria:
inclusion criteria: * patients with mandibular molar implant placement. * presence of contralateral natural mandibular first, second molars or both. * availability of pre-extraction cbct scans of the corresponding or contralateral mandibular molar tooth or panoramic radiographs for mesiodistal angulation. * availability of post-implant cbct scans or panoramic radiographs for mesiodistal angulation exclusion criteria: * incomplete or low-quality cbct scans. * history of mandibular trauma or pathologies altering tooth or implant alignment. * history of reconstructive mandibular surgery in the implant region. * history of periapical pathology
monoclonal antibody against pcsk9 to reduce elevated low-density lipoprotein cholesterol (ldl-c) in adults currently not receiving drug therapy for easing lipid levels

Conditions: Hyperlipidemia

Summary: the primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (amg 145) every 2 weeks (q2w) or every 4 weeks (q4w), compared with placebo, on the percent change from baseline in ldl-c when used as monotherapy in adults with hypercholesterolemia.


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 to ≤ 75 years of age * low density lipoprotein cholesterol (ldl-c) ≥ 100 mg/dl and \< 190 mg/dl * framingham risk score of 10% or less * fasting triglycerides \< 400 mg/dl exclusion criteria: * history of coronary heart disease * new york heart association (nyha) ii - iv heart failure * uncontrolled cardiac arrhythmia * uncontrolled hypertension

Keywords: high cholesterol proprotein convertase subtilisin/kexin type 9 (pcsk9) treatment for high cholesterol lowering cholesterol lowering high cholesterol hypercholesterolemia
perineal massage and warm application in labor

Conditions: Perineal Injury; Pain; Labor

Summary: the aim of this study is to determine the effect of perineal massage and warm compress application at first and second stage of labor on perineal trauma, pain and delivery comfort.

perineal trauma is the damage caused by rupture, laceration or episiotomy during birth. birth-related perineal trauma can lead to many short and long-term physical and psychological morbidities that affect the woman's life. problems such as pain, bleeding and delay in the attachment of mother and newborn appear in the early postpartum period. in the following period problems such as prolapse, incontinence, sexual dysfunction and anxiety may be experienced. this randomised controlled study was executed at a research hospital between may 2018 - september 2019. the sample of study is made consisted of three intervention groups and a control group of total 120 pregnant women by randomisation method. perineal massage, perineal warm compress application, perineal massage and warm compress was done to the intervention groups respectively. nothing was done to the control group. perineal massage was given for 10 minutes, warm compress application was done 30 minutes three times when cervical dilatation 3-4 cm, 5-7 cm and 8-10 cm respectively. the data was collected by using socio-demographic and obstetric data collection form, first and second stage of labor stage data collection form, childbirth comfort scale, newborn data collection form, perineal trauma and bleeding monitorisation/ measurement form, visual analogue scale, birth satisfaction scale and perineal massage and perineal warm compress application satisfaction evaluation form. when evaluating the data; number, percentage, mean, standard deviation, median, anova test, tukey test, kruskal wallis test, paired sample t test, friedman test, ki-square test and fisher's exact was used.

Eligibility criteria:
inclusion criteria: * primiparous * 38"week of pregnancy * singleton pregnancy * cervical dilatation 3"cm * cephalic presentation exclusion criteria: * chronic disease * presence of fetal macrosomia * presence of uterin surgery * presence of fetal anomaly

Keywords: labor perineal massage perineal warm compress perineal trauma
portable monitoring device for the diagnosis of sleep apnea in obese patients

Conditions: Obstructive Sleep Apnea Syndrome; Obesity

Summary: introduction the portable monitoring system (pms) recording of cardiopulmonary parameters (level iii of asda) has been validated in subjects with high probability of obstructive sleep apnea (osa) without comorbidities. however, there is not any study evaluating this system when osa is associated with morbid obesity, so the validation of pms will be very useful in order to properly work-up this highly risk population. objective: to evaluate the accuracy of level iii type of pms - stardust™" (std), on patients with level ii and iii of obesity and high clinical suspicion of osa. methods:participants with bmi \> 35 kg/m2 and with suspicion of osa will consecutively be selected from an outpatients sleep clinic of unifesp. they will be randomized for the following order of recordings: 1) std at home for 1 night 2) std in the sleep lab simultaneous to psg. ahi will be taken for subsequent analysis:a) ahi psg b) ahi std -lab and c) ahi std- home.


Eligibility criteria:
inclusion criteria: * bmi \> 35 * complaints of snoring, sleep apnea, daytime sleepiness exclusion criteria: * use of home oxygen * other sleep diseases * inability to perform psg

Keywords: obesity sleep apnea portable monitoring
precision microbiome directed extension of anti-tnfα crohn's disease therapy in children: the promote trial

Conditions: Inflammatory Bowel Diseases; Crohn Disease

Summary: to determine whether a specific food-origin plant-derived resistant starch (rs) optimized for the individual will increase the abundance of known butyrate producing microbes.


Eligibility criteria:
inclusion criteria: * age between 8.0 to 16.9 years of age. * capable of giving informed consent, or if appropriate, have an acceptable representative capable of giving consent on the participant's behalf. * established crohn's disease (cd) diagnosis with the site of disease involving at least the terminal ileum or ascending colon. * cd is in clinical remission or with mild stable disease activity (weighted pediatric crohn's disease activity index of 0 to 39.5). * receiving infliximab or adalimumab anti-tnfa monoclonal antibody medication for treatment of cd. * no changes in medical treatment for the previous month and without anticipated changes for the next month. * ability and willingness to comply with study procedures (e.g., stool collection) for the entire length of the study. exclusion criteria: * allergy to rs or excipients. * co-existing diagnosis with diabetes mellitus type 1. * treatment with another investigational drug or intervention throughout the study. * current illicit drug or alcohol dependence. * inability or unwillingness of an individual or legal guardian to give written informed consent. * other conditions requiring immunomodulating or biological medications. * pregnancy. * participant's microbiota does not increase butyrate production utilizing any rs from the assembled panel as measured through the rapidaim ex vivo assay.

Keywords: resistant starch microbiome anti-tnf
is sphenopalatine ganglion block treatment effective on postspinal headaches

Conditions: Headache Disorders; Central Nervous System Diseases

Summary: this study evaluates effect of sphenopalatine ganglion block in post dural puncture headache. half of participants will receive standard supportive treatment and other half of patients will be performed sphenopalatine ganglion block.

spinal anesthesia is known subarachnoid block also commonly used regional anesthesia technic. spinal anesthesia is frequently performed in obstetric patients undergoing cesarian section, which has several advantages including less deep vein thrombosis incidence, low opioid requirement, early mobilization and early lactation also has some complications too. postdural headache is one of the most known complications of spinal anesthesia. the etiology of the postspinal headache remains unclear. severeness of the symptoms and amount of the cerebrospinal fluid leakage have been found positive correlating. the cerebrospinal fluid supports brain with it's mass effect. when a leakage of the fluid occurs, support of the brain decreases and pain sensitive structures of the brain gets more sensitive. in this condition 5 th 9th and 10 th cranial nerves, falks cerebelli, tentorium and blood vessels are affected most. decreased cerebrospinal fluid volume causes decreased brain volume and compensatory mechanisms lead to cerebral venous dilatation. conservative treatments are iv hydration, analgesic agents, caffeine or theophylline. epidural blood patch is the gold standard for the treatment . however epidural blood patch is an invasive technic and has some complications such as dural puncture, infection and neurologic trauma. sphenopalatine ganglion is one of the four parasympathetic thin ganglion in skull. parasympathetic fibers innervates cerebral and meningeal blood vessels which cause vasodilatation and stimulate nociceptor activation on meninges. consequently headache is related with sensory cortex. transnasal spg block is performed successfully in chronic pain syndromes including migraine, cluster headaches and atypic face pain. likewise the spg block is performed in acute treatment of postspinal headache. however gold standard of the treatment is epidural blood patching which is interventional and has many risks. several studies enrolled limited participants offer spg block primarily in the literature.

Eligibility criteria:
inclusion criteria: * patients who was diagnosed for postdural puncture headache after cesarian section * patients who is fluent speaking and writing in turkish exclusion criteria: * refusal to participate in the study * patients who was known lidocaine sensitivity * patients with severe nasal septum deviation

Keywords: spinal anesthesia sphenopalatine ganglion block postspinal headache
high-protein food snack for dialysis patients

Conditions: Renal Failure; Albumin; Double; Diet Habit

Summary: the study team aims to provide a food snack that is high in protein (30 g) for two weeks each month (6 treatments per patient per month) for 6 consecutive months, post-dialysis treatment, to in-center hemodialysis patients of all vintages and with all levels and types of comorbidities. the study team will compare changes in serum albumin during the intervention (6 months) using the patients' own serum albumin results that are collected for three months prior to and three months after the intervention. additionally, the study team will determine participants' dietary habits and appetite pre-, during and post-intervention.


Eligibility criteria:
inclusion criteria: * chronic hemodialysis (chd) therapy * active and permanent patients to the area fresenius kidney care (fkc) dialysis clinic * no food allergies or dietary restrictions * no contraindications to consuming anything by mouth as per the medical director and/or personal reporting. exclusion criteria: * patients unable to commit to the full time commitments of the study * those who have food allergies, especially to chicken, pork sausage, eggs, fresh cilantro, red and yellow bell peppers, cucumbers, mrs. dash grill seasoning, newman's own ranch salad dressing, minced garlic, sweet pickle relish, vidalia onions, tomatoes * dietary restrictions as medically indicated, * trouble chewing/swallowing as confirmed by medical director, and/or personal reporting.
european cmr registry

Conditions: Consecutive Patients Undergoing CMR

Summary: 1. the main aim of the first specific protocol initiated by the european cmr registry, suspected cad, is to demonstrate that patients presenting for work up of suspected coronary artery disease, which have a completely normal cmr scan will have a low risk for cardiovascular events. 2. the main aim of the second specific protocol initiated by the european cmr registry, hcm-scd, will be to evaluate cmr for risk stratification in hypertrophic cardiomyopathy(hcm). 3. this registry is sought to collect data on the general use of cmr in the european clinical practice, its safety and its therapeutic implications in a high number of cases to 1) substantiate the clinical yield of cmr and 2) to define additional clinical questions worth to be investigated in detail as additional specific protocols in the future.


Eligibility criteria:
inclusion criteria: - european clinical practice: consecutive patients with accomplished cmr. -suspected-cad: consecutive patients with suspected coronary artery disease undergoing a combined cmr protocol including evaluation of lv function, assessment of myocardial ische¬mia by adenosine stress perfusion or high-dose dobutamine cmr and detection of myocardial infarction using contrast-enhanced cmr. - hcm-scd: consecutive patients with hypertrophic cardiomyopathy undergoing a combined cmr protocol including lv function, rest perfusion, and detection of myocardial scarring by contrast-enhanced cmr. the diagnosis of hypertrophic cardiomyopathy is based on the demonstration of a hypertrophied, non-dilated left ventricle (wall thickness of at least 15 mm in adults or the equivalent relative to body-surface area in children) in the absence of another cardiac or systemic disease capable of producing a similar degree of hypertrophy. in adult relatives of the patients with hypertrophic cardiomyo¬pathy, a wall thickness of 13 mm or more will be considered a criterion for diagnosis. exclusion criteria: * european clinical practice: none * suspected-cad: missing informed consent. patients with known cad by invasive coronary angiography or previous mi. * hcm-scd: missing informed consent. patients with known cad by invasive coronary angiography or previous mi. patients with left ventricular hypertrophy of other causes (e.g. hypertension, valvular heart disease)

Keywords: cmr register cad myocard scarring
molecular imaging of her2 expression in breast cancer using [123i] i-(he)3-g3

Conditions: Primary Breast Cancer

Summary: the study should evaluate distribution of \[123i\] i-(he)3-g3 in patients with primary her2-positive and her2-negative breast cancer

overall goal of the project: to determine her2 expression level in primary breast cancer before neoadjuvant system therapy. phase i. distribution of he3-g3 (\[123i\] i-(he)3-g3) in patients with primary breast cancer. the study should evaluate distribution of he3-g3 (\[123i\] i-(he)3-g3) in patients with primary her2-positive and her2-negative breast cancer.

Eligibility criteria:
inclusion criteria: 1. subject is \> 18 years of age 2. availability of results from her2 status previously determined on material from the primary tumor and metastatic ln, either a. her2-positive, defined as a dako herceptest™ score of 3+ or fish positive or b. her2-negative, defined as a dako herceptest™ score of 0 or 1+; or else if 2+ then fish negative 3. hematological, liver and renal function test results within the following limits: * white blood cell count: \> 2.0 x 109/l * hemoglobin: \> 80 g/l * platelets: \> 50.0 x 109/l * alt, alp, ast: =\< 5.0 times upper limit of normal * bilirubin =\< 2.0 times upper limit of normal * serum creatinine: within normal limits 4. a negative pregnancy test for all patients of childbearing potential. sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination 5. subject is capable to undergo the diagnostic investigations to be performed in the study 6. informed consent exclusion criteria: 1. any system therapy (chemo-/targeted therapy) 2. second, non-breast malignancy 3. active current autoimmune disease or history of autoimmune disease 4. active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) 4. known hiv positive or chronically active hepatitis b or c 5. administration of other investigational medicinal product within 30 days of screening 6. ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to us national cancer institute's
fgf-23 suppressibility by calcitonin

Conditions: Hypophosphatemia

Summary: introduction: based on our experience with calcitonin as an fgf-23 suppressive agent in a patient with an fgf-23 producing tumor we hypothesize that calcitonin may be a physiologically important regulator of fgf-23 production and secretion in healthy humans. aim: in this study we wish to examine the fgf-23 suppressive effects of calcitonin in healthy men. study design: placebo-controlled, cross-over study method: * all twelve subjects are examined on two occasions, once after exposure to placebo 1 ml nacl 0.9% subcutaneously, and once following calcitonin 200 iu/ml subcutaneously * on both occasions frequent bloodsampling will take place, out an indwelling catheter in de forearm vein. * sampling times: -15, 0, 60, 120, 240, 360, and 480 minutes * mealtimes: calcium and phosphate intake standardized on both occasions * all samples are analyzed for fgf-23, using a c-terminal fgf-23 elisa kit (immunotopics, san clemente, usa) that measures intact and c-terminal fragments of fgf-23, and one that measures only intact fgf-23 * samples obtained at t-15, t0, t240 and t480 are stored for later analysis of ca, albumin, po4, pth, 25-ohd and 1,25-ohd endpoint: a change of 25% in de serum fgf-23 levels in response to a single subcutaneous injection of calcitonin 200 iu.


Eligibility criteria:
inclusion criteria: * healthy man, who are between 20-55 years old, and have a bmi 20-27 kg/m2. exclusion criteria: * serum creatinin \>100 mmol/l, or glomerular filtration rate \<80 ml/min. * abnormal serum ca, po4, albumin, 25-oh vitamin d, or pth levels. * any medication.

Keywords: fibroblast growth factor - 23 calcitonin